Neuropeptides
Volume 41, Issue 1 , Pages 25-31 , February 2007

Substance P stimulates late-stage rat osteoblastic bone formation through neurokinin-1 receptors

  • T. Goto

      Affiliations

    • Division of Anatomy, Kyushu Dental College, 2-6-1 Manazuru, Kitakyushu 803-8580, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 93 582 1131; fax: +81 93 591 8199.
    • ,
  • K. Nakao

      Affiliations

    • Division of Orofacial Functions and Orthodontics, Kyushu Dental College, Kitakyushu 803-8580, Japan
    • ,
  • K.K. Gunjigake

      Affiliations

    • Division of Orofacial Functions and Orthodontics, Kyushu Dental College, Kitakyushu 803-8580, Japan
    • ,
  • M.A. Kido

      Affiliations

    • Laboratory of Oral Anatomy and Cell Biology, Graduate School of Dental Science, Kyushu University, Fukuoka 812-8582, Japan
    • ,
  • S. Kobayashi

      Affiliations

    • Division of Anatomy, Kyushu Dental College, 2-6-1 Manazuru, Kitakyushu 803-8580, Japan
    • ,
  • T. Tanaka

      Affiliations

    • Laboratory of Oral Anatomy and Cell Biology, Graduate School of Dental Science, Kyushu University, Fukuoka 812-8582, Japan

Received 4 May 2006 ,Accepted 8 November 2006.

References 

  1. Adamus MA, Dabrowski ZJ. Effect of the neuropeptide substance P on the rat bone marrow-derived osteogenic cells in vitro. J. Cell Biochem. 2001;81:499–506
  2. Azuma H, Kido J, Ikedo D, Kataoka M, Nagata T. Substance P enhances the inhibition of osteoblastic cell differentiation induced by lipopolysaccharide from Porphyromonas gingivalis. J. Periodontol. 2004;75:974–981
  3. Bellows CG, Aubin JE, Heersche JNM, Antosz ME. Mineralized bone nodules formed in vitro from enzymatically released rat calvaria cell populations. Calcif. Tissue Int. 1986;38:143–154
  4. Bjurholm A. Neuroendocrine peptides in bone. Int. Orthop. 1991;15:325–329
  5. Bjurholm A, Kreicbergs A, Brodin E, Schultzberg M. Substance P- and CGRP-immunoreactive nerves in bone. Peptides. 1988;9:165–171
  6. Bjurholm A, Kreicbergs A, Schultzberg M, Lerner UH. Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR-106-01, ROS 17/2.8, MC3T3-E1, and Saos-2) and primary bone cells. J. Bone Miner. Res. 1992;7:1011–1019
  7. Fujii T, Murai M, Morimoto H, Maeda Y, Yamaoka M, Hagiwara D, et al. Pharmacological profile of a high affinity dipeptide NK1 receptor antagonist, FK888. Br. J. Pharmacol. 1992;107:785–789
  8. Goto T, Yamaza T, Kido MA, Tanaka T. Light- and electron-microscopic study of the distribution of axons containing substance P and the localization of neurokinin-1 receptor in bone. Cell Tissue Res. 1998;293:87–93
  9. Goto T, Yamaza T, Kido MA, Tanaka T. Substance P activates osteoclast formation and osteoclastic bone resorption through the neurokinin-1 receptor. Acta Histochem. Cytochem. 2001;34:31–38
  10. Grimsholm O, Rantapaa-Dahlqvist S, Forsgren S. Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis. Arthritis Res. Ther. 2005;7:R416–R426
  11. Kawase T, Okuda K, Burns DM. Immature osteoblastic MG63 cells possess two calcitonin gene-related peptide receptor subtypes that respond differently to [Cys(Acm)(2,7)] calcitonin gene-related peptide and CGRP(8–37). Am. J. Physiol. Cell Physiol. 2005;289:C811–C818
  12. Lembeck F, Holzer P. Substance P as neurogenic mediator of antidromic vasodilation and neurogenic plasma extravasation. Naunyn Schmiedebergs Arch. Pharmacol. 1979;310:175–183
  13. Lerner UH. Neuropeptidergic regulation of bone resorption and bone formation. J. Musculoskelet. Neuronal. Interact. 2002;2:440–447
  14. Lundberg P, Lundgren I, Mukohyama H, Lehenkari PP, Horton MA, Lerner UH. Vasoactive intestinal peptide (VIP)/pituitary adenylate cyclase-activating peptide receptor subtypes in mouse calvarial osteoblasts: presence of VIP-2 receptors and differentiation-induced expression of VIP-1 receptors. Endocrinology. 2001;142:339–347
  15. Maayan C, Bar-On E, Foldes AJ, Gesundheit B, Pollak RD. Bone mineral density and metabolism in familial dysautonomia. Osteoporos. Int. 2002;13:429–433
  16. Michelangeli VP, Fletcher AE, Allan EH, Nicholson GC, Martin TJ. Effects of calcitonin gene-related peptide on cyclic AMP formation in chicken, rat, and mouse bone cells. J. Bone Miner. Res. 1989;4:269–272
  17. Mori T, Ogata T, Okumura H, Shibata T, Nakamura Y, Kataoka K. Substance P regulates the function of rabbit cultured osteoclast; increase of intracellular free calcium concentration and enhancement of bone resorption. Biochem. Biophys. Res. Commun. 1999;262:418–422
  18. Nicoll RA, Schenker C, Leeman SE. Substance P as a transmitter candidate. Annu. Rev. Neurosci. 1980;3:227–268
  19. Olgart L, Gazelius B, Brodin E, Nilsson G. Release of substance P-like immunoreactivity from the dental pulp. Acta Physiol. Scand. 1977;101:510–512
  20. Otsuka M, Yoshioka K. Neurotransmitter functions of mammalian tachykinins. Physiol. Rev. 1993;73:229–308
  21. Sakagami Y, Girasole G, Yu XP, Boswell HS, Manolagas SC. Stimulation of interleukin-6 production by either calcitonin gene-related peptide or parathyroid hormone in two phenotypically distinct bone marrow-derived murine stromal cell lines. J. Bone Miner. Res. 1993;8:811–816
  22. Sherman BE, Chole RA. A mechanism for sympathectomy-induced bone resorption in the middle ear. Otolaryngol. Head Neck Surg. 1995;113:569–581
  23. Shih C, Bernard GW. Neurogenic substance P stimulates osteogenesis in vitro. Peptides. 1997;18:323–326
  24. Togari A, Arai M, Mizutani S, Mizutani S, Koshihara Y, Nagatsu T. Expression of mRNAs for neuropeptide receptors and beta-adrenergic receptors in human osteoblasts and human osteogenic sarcoma cells. Neurosci. Lett. 1997;233:125–128

PII: S0143-4179(06)00149-1

doi: 10.1016/j.npep.2006.11.002

Neuropeptides
Volume 41, Issue 1 , Pages 25-31 , February 2007

Article Tools

* Image Usage & Resolution